The challenges in making animal models of complex human epilepsy phenotypes with varied aetiology highlights the need to develop alternative disease models that can address the limitations of animal models by effectively recapitulating human pathophysiology. The advances in stem cell technology provide an opportunity to use human iPSCs to make disease-in-a-dish models. The focus of this review is to report the current information and progress in the generation of epileptic patient-specific iPSCs lines, isogenic control cell lines, and neuronal models. These in vitro models can be used to study the underlying pathological mechanisms of epilepsies, anti-seizure medication resistance, and can also be used for drug testing and drug screening with their isogenic control cell lines.
1 May 2022 in Journal of Molecular Graphics and Modelling
Valproic acid (VPA) is a first‐line antiseizure medication (ASM) that is highly efficacious for treating generalized and focal epilepsy disorders. Unfortunately, due to its strong association with teratogenic effects culminating in fetal valproate spectrum disorder (FVSD), which may include neurocognitive and neurobehavioral deficits, the drug has become highly regulated/restricted for women of childbearing potential. This includes those who have been shown to respond well to the drug and respond poorly to alternative ASMs. Concurrently, VPA's neurotoxic, teratogenic mechanisms have been studied in vitro, and continued research may aid in providing depth to our understanding so that superior evidence‐based care plans and novel drug designs can be made for patients with epilepsy disorders. This scoping review systematically assesses what in vitro studies have discovered regarding VPA's effects on neural cells and the proposed cellular neurotoxic mechanisms. Neurotoxicity studies have captured the cytotoxic, dysmorphological, genetic, and epigenetic effects in murine and human primary, immortalized, and stem cells in vitro. This includes extensive identification of many genes and gene pathways associated with neurodevelopmental disorders, a hallmark of FVSD. Although published studies have illuminated much about VPA's neurotoxic, teratogenic effects, a lack of standardization in testing methodologies renders making direct comparisons between the results of different studies challenging. Nevertheless, the recent use of human stem cell‐based models provides a richer understanding of what cellular, molecular, genetic, and epigenetic effects are caused by VPA exposure. Future in vitro studies may improve their clinical translatability by administering clinically relevant concentrations of VPA to human stem cell‐derived neural cells and fostering a better understanding of VPA's neural cell type‐specific and epigenetic effects. In vitro VPA neurotoxicity studies on neurodevelopment show a clear potential to provide data that may help construct superior personalized evidence‐based treatment plans and novel drug designs for women of childbearing potential with epilepsy disorders.
1 January 2017 in Critical Reviews™ in Eukaryotic Gene Expression
Regenerative medicines are used to restore the normal function of the damaged organs and tissues to repair them or replace them with functional ones using a complex surgical process. Stem cells are the cells that have self renewal capacity as well as have the capability to differentiate into specialized and specific cell lineages to repair or replace the damaged tissue or organ. So, the problems that are faced during transplantation are overcome through stem cells. There are a number of sources of stem cells and their differentiation abilities are vary according to their sources such as some cells give rise to all cell types, while some are not. Sources of stem cells are embryo, adipose tissues, amniotic fluid, bone marrow etc. and cell type specific stem cells such as dental pulp stem cells etc. Stem cells have proved their importance and potential as regenerative medicines form fatal diseases such as damaging of heart, kidney, lung and liver to less fatal diseases such as osteoporosis and damaging of teeth. Stem cells also used in the enhancement of the aesthetic value of a person through plastic or reconstructive surgery. Paracrine factors and the surrounding environment also have impact on the working of stem cells.
Objective: Current preclinical epilepsy drug screening relies on animal models that poorly reflect human neurophysiology, leading to high failure rates in clinical translation. We aimed to establish a human in vitro model using human‐induced pluripotent stem cell (hiPSC)–derived cortical neurons cultured on multielectrode arrays (MEAs), capable of generating precisely controlled after‐discharges (ADs) through electrical stimulation. We optimized stimulation parameters to evoke epileptiform‐like hypersynchronous events and validated the model using six approved antiseizure medications (ASMs). Methods: hiPSCs were rapidly differentiated into NGN2 cortical neurons and co‐cultured with astrocytes on a 12‐electrode, 24‐well MEA. Network activity was tracked weekly. Upon maturation, biphasic voltage stimuli (400–2000 mV, 10 pulses at 100 Hz, 100 μs phase width) were applied in 100 ms trains to induce ADs. Stimulation intensity was increased until a maximum spike count per burst was reached. The timing of the stimulating inter‐burst interval (IBI) was shortened from 10 to 1 s. We tested six ASMs with distinct mechanisms of action for their ability to attenuate induced ADs, as measured by the area under the curve (AUC) of spikes within bursts. Results: A ±1000 mV stimulus was sufficient to evoke robust ADs; higher voltages caused network instability without enhancing response strength. The maximum hypersynchronous bursting rate was observed with 2 s IBIs, whereas attempts to induce more frequent events using 1 s IBIs led to desynchronization and a reduction in burst frequency below baseline. Phenytoin, perampanel, clonazepam, and lamotrigine significantly reduced AUC within 5 min in a concentration‐dependent manner. Vigabatrin and levetiracetam required longer pre‐incubations: AUC was reduced after 6 h for levetiracetam and at 24 h for vigabatrin. Significance: We present a novel hiPSC‐derived, electrically induced in vitro model for screening ASM candidates. This approach captures human‐relevant epileptiform dynamics, allows fine control over stimulation parameters, and enables testing of diverse drug mechanisms. Its compatibility with high‐throughput platforms makes it a promising tool for ASM discovery and personalized treatment strategies.
This study was undertaken to systematically evaluate the efficacy of cell therapy in reducing seizures in animal models of chronic epilepsy. Three databases, Ovid MEDLINE, Ovid Embase, and Web of Science, were searched using predetermined eligibility criteria. The relevant preclinical controlled studies were included for review and meta‐analysis using a random‐effects model to calculate summary estimates of the effect size (percentage reduction in seizures). The degree of heterogeneity among the included studies was assessed using the I2 statistic. Subgroup meta‐analysis and meta‐regression were performed to further elucidate the sources of heterogeneity. Thirty published studies met the eligibility criteria, including a total of 1306 animals. The majority of studies used kainic acid and pilocarpine status epilepticus models of mesial temporal lobe epilepsy (MTLE). The random effects model revealed an overall reduction in seizure frequency of 54.8% (95% confidence interval = 48.0558–61.5455) compared to the control, and the heterogeneity was 87.1% among the included studies. The meta‐regression revealed that seven study characteristics significantly accounted for the between‐study heterogeneity. They can be grouped into three broad categories: epilepsy‐specific, animal‐specific, and cell transplantation‐specific. The greatest seizure reduction was observed in the post‐kainic acid status epilepticus model of chronic MTLE, when the cells were delivered intravenously and when the seizure reduction was measured as seizure frequency. Embryonic stem cell transplantation showed the greatest efficacy in reducing seizures. Cell transplantation shows favorable efficacy as a treatment that can reduce seizure recurrence in chronic animal models of epilepsy. High heterogeneity between studies reflects the diverse methodologies employed in preclinical research on cell therapy for epilepsy. Despite these encouraging findings, the high risk of publication bias and variability in study design emphasize the need for further robust preclinical studies to confirm these reported outcomes.